Drug intelligence / Profile preview

doxorubicin + docetaxel + trastuzumab

Development stage: Preclinical
Lead developer: Roche
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous

Overview

A three-drug antineoplastic regimen combining the anthracycline doxorubicin, the taxane docetaxel, and the anti-HER2 monoclonal antibody trastuzumab. It is used in research and some clinical settings for HER2-positive breast cancer, particularly in neoadjuvant or metastatic contexts. Mechanistically: doxorubicin intercalates DNA and inhibits topoisomerase II, generating DNA damage and free radicals; docetaxel stabilizes microtubules, preventing cell division; trastuzumab targets HER2 (ERBB2), inhibiting downstream signaling, mediating antibody-dependent cellular cytotoxicity, and promoting HER2 internalization. Concurrent use of conventional anthracyclines with trastuzumab has notable cardiotoxicity risk; some studies substitute pegylated liposomal doxorubicin to mitigate this risk.

Other names: doxorubicin plus docetaxel plus trastuzumabDOX + DOC + trastuzumabanthracycline + taxane + trastuzumab

Targets

DNATUBB (Tubulin (alpha and beta subunits))FCGR3A (Low affinity immunoglobulin gamma Fc region receptor III-A)TOP2A (DNA topoisomerase II)

Beyond the preview

Go deeper on doxorubicin + docetaxel + trastuzumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on doxorubicin + docetaxel + trastuzumab.

Explore the full profile